Screener
Corvus Pharmaceuticals CRVS Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 29 | 22 |
| Accretion related to marketable securities | (17) | (291) |
| Stock-based compensation | 2,650 | 1,251 |
| Change in fair value of warrant liability | — | (25,129) |
| Loss from equity method investment | 599 | 539 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable - related party | (6) | (4) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Corvus Pharmaceuticals's stock-based comp?
- Corvus Pharmaceuticals (CRVS) reported stock-based comp of $2.65M in Q1 2026.
- How has Corvus Pharmaceuticals's stock-based comp changed year-over-year?
- Corvus Pharmaceuticals's stock-based comp increased by 111.8% year-over-year, from $1.25M to $2.65M.
- What is the long-term trend for Corvus Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), Corvus Pharmaceuticals's stock-based comp has grown at a 5.9% compound annual growth rate (CAGR), from $4.23M to $5.33M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Corvus Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude